These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 27885740)

  • 1. ASP5878, a selective FGFR inhibitor, to treat FGFR3-dependent urothelial cancer with or without chemoresistance.
    Kikuchi A; Suzuki T; Nakazawa T; Iizuka M; Nakayama A; Ozawa T; Kameda M; Shindoh N; Terasaka T; Hirano M; Kuromitsu S
    Cancer Sci; 2017 Feb; 108(2):236-242. PubMed ID: 27885740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer.
    Weickhardt AJ; Lau DK; Hodgson-Garms M; Lavis A; Jenkins LJ; Vukelic N; Ioannidis P; Luk IY; Mariadason JM
    BMC Cancer; 2022 May; 22(1):478. PubMed ID: 35501832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27/Kip1 and G1/G0 arrest.
    Miyake M; Ishii M; Koyama N; Kawashima K; Kodama T; Anai S; Fujimoto K; Hirao Y; Sugano K
    J Pharmacol Exp Ther; 2010 Mar; 332(3):795-802. PubMed ID: 19955487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
    Sootome H; Fujita H; Ito K; Ochiiwa H; Fujioka Y; Ito K; Miura A; Sagara T; Ito S; Ohsawa H; Otsuki S; Funabashi K; Yashiro M; Matsuo K; Yonekura K; Hirai H
    Cancer Res; 2020 Nov; 80(22):4986-4997. PubMed ID: 32973082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.
    Chell V; Balmanno K; Little AS; Wilson M; Andrews S; Blockley L; Hampson M; Gavine PR; Cook SJ
    Oncogene; 2013 Jun; 32(25):3059-70. PubMed ID: 22869148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1-4, as a single dose and multiple doses in patients with solid malignancies.
    Yamamoto N; Ryoo BY; Keam B; Kudo M; Lin CC; Kunieda F; Ball HA; Moran D; Komatsu K; Takeda K; Fukuda M; Furuse J; Morita S; Doi T
    Invest New Drugs; 2020 Apr; 38(2):445-456. PubMed ID: 31041575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations.
    Lima NC; Atkinson E; Bunney TD; Katan M; Huang PH
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32370101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Role of FGFR Alterations and FGFR mRNA Expression in Metastatic Urothelial Cancer Undergoing Checkpoint Inhibitor Therapy.
    Tully KH; Jütte H; Wirtz RM; Jarczyk J; Santiago-Walker A; Zengerling F; Breyer J; Sikic D; Kriegmair MC; von Hardenberg J; Wullich B; Taubert H; Weyerer V; Stoehr R; Bolenz C; Burger M; Porubsky S; Hartmann A; Roghmann F; Erben P; Eckstein M
    Urology; 2021 Nov; 157():93-101. PubMed ID: 34153367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ASP5878, a Novel Inhibitor of FGFR1, 2, 3, and 4, Inhibits the Growth of FGF19-Expressing Hepatocellular Carcinoma.
    Futami T; Okada H; Kihara R; Kawase T; Nakayama A; Suzuki T; Kameda M; Shindoh N; Terasaka T; Hirano M; Kuromitsu S
    Mol Cancer Ther; 2017 Jan; 16(1):68-75. PubMed ID: 27837028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398.
    Datta J; Damodaran S; Parks H; Ocrainiciuc C; Miya J; Yu L; Gardner EP; Samorodnitsky E; Wing MR; Bhatt D; Hays J; Reeser JW; Roychowdhury S
    Mol Cancer Ther; 2017 Apr; 16(4):614-624. PubMed ID: 28255027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibroblast growth factor receptor (
    Al-Obaidy KI; Cheng L
    J Clin Pathol; 2021 Aug; 74(8):491-495. PubMed ID: 33731335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma.
    Milowsky MI; Dittrich C; Durán I; Jagdev S; Millard FE; Sweeney CJ; Bajorin D; Cerbone L; Quinn DI; Stadler WM; Rosenberg JE; Lochheed M; Sen P; Squires M; Shi M; Sternberg CN
    Eur J Cancer; 2014 Dec; 50(18):3145-52. PubMed ID: 25457633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells.
    Wang J; Mikse O; Liao RG; Li Y; Tan L; Janne PA; Gray NS; Wong KK; Hammerman PS
    Oncogene; 2015 Apr; 34(17):2167-77. PubMed ID: 24909170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
    Wang L; Šuštić T; Leite de Oliveira R; Lieftink C; Halonen P; van de Ven M; Beijersbergen RL; van den Heuvel MM; Bernards R; van der Heijden MS
    Eur Urol; 2017 Jun; 71(6):858-862. PubMed ID: 28108151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Effect of FGFR Mutations or Gene Fusions in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Results from a Large, Single-institution Cohort.
    Necchi A; Lo Vullo S; Raggi D; Gloghini A; Giannatempo P; Colecchia M; Mariani L
    Eur Urol Focus; 2019 Sep; 5(5):853-856. PubMed ID: 29525380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.
    Lamont FR; Tomlinson DC; Cooper PA; Shnyder SD; Chester JD; Knowles MA
    Br J Cancer; 2011 Jan; 104(1):75-82. PubMed ID: 21119661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations.
    Balasooriya ER; Wu Q; Ellis H; Zhen Y; Norden BL; Corcoran RB; Mohan A; Martin E; Franovic A; Tyhonas J; Lardy M; Grandinetti KB; Pelham R; Soroceanu L; Silveira VS; Bardeesy N
    Clin Cancer Res; 2024 May; 30(10):2181-2192. PubMed ID: 38437671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with
    Pal SK; Rosenberg JE; Hoffman-Censits JH; Berger R; Quinn DI; Galsky MD; Wolf J; Dittrich C; Keam B; Delord JP; Schellens JHM; Gravis G; Medioni J; Maroto P; Sriuranpong V; Charoentum C; Burris HA; Grünwald V; Petrylak D; Vaishampayan U; Gez E; De Giorgi U; Lee JL; Voortman J; Gupta S; Sharma S; Mortazavi A; Vaughn DJ; Isaacs R; Parker K; Chen X; Yu K; Porter D; Graus Porta D; Bajorin DF
    Cancer Discov; 2018 Jul; 8(7):812-821. PubMed ID: 29848605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.
    Nakanishi Y; Akiyama N; Tsukaguchi T; Fujii T; Sakata K; Sase H; Isobe T; Morikami K; Shindoh H; Mio T; Ebiike H; Taka N; Aoki Y; Ishii N
    Mol Cancer Ther; 2014 Nov; 13(11):2547-58. PubMed ID: 25169980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complexity of FGFR signalling in metastatic urothelial cancer.
    Rodriguez-Vida A; Saggese M; Hughes S; Rudman S; Chowdhury S; Smith NR; Lawrence P; Rooney C; Dougherty B; Landers D; Kilgour E; Arkenau HT
    J Hematol Oncol; 2015 Oct; 8():119. PubMed ID: 26497743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.